11.3 Generic Substitution & Product Selection
Key Takeaways
- Illinois drug product selection is authorized under 225 ILCS 85 §25 and defined with 410 ILCS 620/3.14 of the Illinois Food, Drug and Cosmetic Act.
- If the prescriber does not prohibit selection, a pharmacist may dispense a different brand or nonbrand product of the same generic name with a lower unit price, using FDA therapeutically equivalent generics.
- FDA Orange Book A-rated (therapeutically equivalent) products are the standard interchange framework; B-rated products are not treated as freely interchangeable equivalents.
- Prescriber “may not substitute” / DAW / brand medically necessary instructions block generic selection; patients may also request the brand when substitution is otherwise allowed.
- When substitution occurs, record the manufacturer (or other required identification) of the product dispensed; biosimilar interchange follows FDA interchangeable designations rather than inventing Illinois-only bans.
11.3 Generic Substitution & Product Selection
Quick Answer: Under 225 ILCS 85 §25 (with 410 ILCS 620/3.14 of the Illinois Food, Drug and Cosmetic Act), if the prescriber does not prohibit drug product selection, a pharmacist may dispense a different brand or nonbrand product of the same generic name that has a unit price less than the product specified—using generics the FDA has determined therapeutically equivalent (Orange Book A-rated framework). Honor “may not substitute” / DAW / brand medically necessary orders. Record the manufacturer of the product dispensed. Patients may still prefer brand when selection is otherwise allowed.
NABP Area 4 (Pharmacy Operations) includes product selection. The Illinois MPJE tests whether you know when you may swap brands, what equivalence standard applies, and what documentation follows the swap.
Statutory Framework
Definitions and cross-references
The Pharmacy Practice Act defines drug product selection as the interchange for a prescribed pharmaceutical product in accordance with Section 25 of the Act and Section 3.14 of the Illinois Food, Drug and Cosmetic Act. That dual citation is intentional: pharmacy practice authority and food/drug misbranding-substitution rules work together. Dispensing a different drug without lawful selection authority is not “customer service”—it can be illegal substitution under 410 ILCS 620/3.14 concepts.
Core permission in 225 ILCS 85 §25
Key statutory conditions (teaching paraphrase of the Act’s structure):
- The prescriber, when transmitting an oral or written prescription, does not prohibit drug product selection
- The pharmacist may dispense a different brand name or nonbrand name product of the same generic name
- The selected drug has a unit price less than the drug product specified on the prescription
- A generic determined therapeutically equivalent by the FDA is available for substitution in Illinois under the Act and the Illinois Food, Drug and Cosmetic Act (with manufacturer notification pathways described in statute for public-health tracking)
Price condition matters on exams: Illinois links selection to a lower unit price than the product prescribed. Selecting a more expensive brand “just because” is not the statutory selection model.
Prescriber “may not substitute” mechanics
Section 25 requires prescription forms to include a signature line and the words “may not substitute.” The prescriber, in his or her own handwriting, places a mark beside “may not substitute” to block selection. Preprinted or rubber-stamped marks (and other deviations from the required format) are not permitted under the statutory format language. The prescriber signs in their own handwriting to authorize issuance.
Modern e-prescribing systems express the same clinical intent with structured DAW fields. Teach both paper-era statutory language and electronic practice reality:
| Intent | Typical expression | Pharmacist action |
|---|---|---|
| Substitution allowed | No prohibition; DAW 0 / blank | May select lower-unit-price TE generic |
| Prescriber demands brand | Handwritten “may not substitute,” “brand medically necessary,” DAW 1 | Dispense brand as ordered |
| Patient demands brand | Patient request when selection otherwise allowed | Dispense brand; bill/DAW coding per payer rules |
| Generic not available | Stockout of TE product | Contact prescriber or use lawful alternative pathway—do not invent non-equivalent swaps |
FDA Orange Book: Therapeutic Equivalence
A-rated vs B-rated (exam core)
The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) assigns therapeutic equivalence (TE) codes:
- A-rated products are considered therapeutically equivalent to the reference listed drug (same active ingredient, dosage form, route, strength; bioequivalence demonstrated under FDA standards)
- B-rated products are not considered therapeutically equivalent at that time
Illinois §25 points you to FDA therapeutic equivalence as the scientific gate for generic availability/substitution. Practical rule:
- A-rated → eligible for ordinary generic interchange (subject to DAW/price/statutory conditions)
- B-rated or unrated → do not treat as freely interchangeable “same generic” under the TE model
Pharmaceutical equivalence vs therapeutic equivalence
| Concept | Meaning |
|---|---|
| Pharmaceutical equivalents | Same active ingredient, strength, dosage form, route |
| Bioequivalence | Comparable rate/extent of absorption under study conditions |
| Therapeutic equivalents (A-rated) | Pharmaceutical equivalents expected to have the same clinical effect and safety profile when administered as labeled |
An ANDA generic must show bioequivalence to the reference listed drug—not superior efficacy, not a new mechanism of action.
Documentation When You Select
Section 25 requires that in every case where selection is made as permitted by the Illinois Food, Drug and Cosmetic Act, the pharmacist indicate on the pharmacy record of the filled prescription the name or other identification of the manufacturer of the drug dispensed. Why exams care:
- Recalls are manufacturer-lot specific
- Therapeutic response complaints need product identity
- Diversion/quality investigations need a clear chain of what left the pharmacy
Labeling should also identify the product the patient actually received (established/proprietary name as required)—do not leave the patient thinking they received Brand X if you dispensed Manufacturer Y’s generic without transparent labeling.
Patient Rights and Counseling Touchpoints
Even when the prescriber allows selection:
- The patient may prefer the brand and decline the generic (subject to cost/coverage consequences you should explain honestly)
- When substitution occurs, good practice—and many payer/plan expectations—includes informing the patient that a generic equivalent is being dispensed
- Appearance changes (shape/color) are a major adherence risk; warn patients that the same medicine may look different
Failure to communicate a swap is how “I thought they gave me the wrong drug” complaints become Board matters.
Narrow Therapeutic Index and Clinical Judgment
Some drugs have a narrow therapeutic index (NTI) (e.g., certain anticonvulsants, thyroid preparations, transplant immunosuppressants historically discussed in equivalence debates). Illinois does not require you to invent a free-standing absolute NTI ban list on the MPJE unless a stem supplies a specific legal prohibition. Correct professional approach:
- Check Orange Book TE code
- Honor any prescriber DAW / may not substitute
- Use clinical judgment and, when needed, contact the prescriber before switching products mid-therapy on sensitive agents
- Document the decision
Do not claim Illinois categorically forbids all generic interchange for every NTI drug if the statute/Orange Book still treat a product as A-rated and the prescriber did not prohibit selection—teach judgment + DAW + TE codes, not folklore bans.
Biosimilars (High Level—No Invented Illinois Bans)
Biosimilars are not classic small-molecule “generics.” They are highly similar biological products evaluated under a different FDA pathway. Key teaching points for Illinois MPJE without inventing unpublished state bans:
- FDA Purple Book resources identify licensed biologics, biosimilars, and interchangeable biosimilars
- Interchangeable designation is the federal concept closest to automatic pharmacy-level substitution of biologics (subject to state law)
- Non-interchangeable biosimilars may still be used when the prescriber specifically orders that product—they are not “wrong,” but they are not automatic Orange-Book-style swaps
- Follow any Illinois-specific biosimilar notification or documentation rules if a vignette states them; if not stated, do not invent absolute prohibitions—apply prescriber intent + FDA interchangeability + professional standards
Worked Examples
Example 1. Prescription: Lipitor 20 mg. No “may not substitute.” A-rated atorvastatin generic available at lower unit price. → Selection permitted; record manufacturer; label the product dispensed.
Example 2. Prescription: brand with handwritten mark at “may not substitute” / DAW 1 “brand medically necessary.” → Dispense brand; no generic swap.
Example 3. Patient requests brand Zoloft despite open substitution. → Patient choice; dispense brand if stocked/ordered; explain cost.
Example 4. Only B-rated product available for a reference brand. → Do not treat as TE automatic substitute; contact prescriber for authorization of a specific product.
Common Traps
- Substituting when the prescriber prohibited selection
- Ignoring the lower unit price condition in Illinois §25
- Using B-rated products as if they were A-rated
- Failing to record manufacturer after selection
- Confusing therapeutic interchange across different molecules (e.g., switching lisinopril to losartan without a new order) with generic product selection of the same generic name
- Inventing absolute Illinois NTI or biosimilar bans not given in the stem
Master §25 + 3.14, Orange Book A ratings, DAW / may not substitute, manufacturer documentation, and patient preference. Section 11.4 covers emergency supply, OTC/BTC, and pseudoephedrine limits when ordinary prescriptions are not available.
Under 225 ILCS 85 §25, when a prescriber does not prohibit drug product selection, a pharmacist may generally:
In Illinois, which prescriber action most clearly directs the pharmacist not to perform generic drug product selection on a written prescription format contemplated by Section 25?
FDA Orange Book “A” therapeutic equivalence ratings are best used in Illinois product-selection analysis to identify:
When an Illinois pharmacist performs lawful drug product selection, which documentation step is required under Section 25?